| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.26 | 2e-05 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.11 | 0.08 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.1 | 0.1 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.1 | 0.1 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.085 | 0.1 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.072 | 0.2 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.069 | 0.3 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.067 | 0.3 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.058 | 0.3 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.052 | 0.4 |